richard_cm_jones

Mereo BioPharma appoint Richard Jones as CFO

pharmafile | November 14, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mereo BioPharma 

Mereo BioPharma, a UK-based biopharmaceutical company, has announced that Richard CM Jones has been appointed chief financial officer of the company and will join the board of directors in the early stages of 2017.

Mereo BioPharma are a specialty biopharmaceutical company that focuses upon the acquisition and development of medicines. They currently have three drugs in their mid-stage portfolio, that were acquired from Novartis.

Richard Jones will move to Mereo from Shield Therapeutics, where he operated as chief financial officer and company secretary. He has been at Shield since 2010, as a non-executive director, before taking on the aforementioned positions in 2011. Prior to moving into the pharmaceutical industry, Richard had worked in investment banking with roles at Investec and Brewin Dolphin Securities.

Advertisement

Richard Jones will replace Richard Bungay, Mereo’s current CFO who has resigned from the board of directors and will leave his position in April 2017.

Dr Denise Scots-Knight, chief executive officer of Mereo BioPharma commented: “I am delighted to announce the appointment of Richard Jones as our Chief Financial Officer and to the Board of Directors. His extensive financial experience in the healthcare industry, initially as an investment banker in the sector and more recently as CFO of Shield Therapeutics, complements that of the other members of Mereo’s executive team. Following our positive debut as a listed company, the Board is confident that Richard will make a valuable and significant contribution to Mereo’s future success.”

Related Content

astrazeneca_sign_sky

AstraZeneca licenses genetic disease drug to Mereo Biopharma for $5 million, becomes shareholder

AstraZeneca has agreed to license AZD9668, its experimental drug for the treatment of alpha-1 antitrypsin …

The Gateway to Local Adoption Series

Latest content